Pharmaceutical compositions

Details Pharmaceutical compositions Pharmaceutical compositions

1997-01-20

2010-12-28

Anderson, James D (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S011400, C514S326000

Reissue Patent

active

RE042014

ABSTRACT:
A process for preparing an emulsion composition comprising a cyclosporin, a rapamycin or an ascomycin or a derivative thereof as active agent, which process comprises the step of admixing to a placebo fat emulsion a concentrate comprisinga) the active agent,b) a stabiliser selected from a phospholipid, a glycolipid, a sphingolipid, a diacylphosphatidyl glycerol, an egg-phosphatidylglycerol, a soy-phosphatidylglycerol, a diacylphosphatidylglycerol, or a salt thereof; or a saturated, mono- or di-unsaturated (C12-24) fatty acid, or a salt thereof, andc) an organic solvent,wherein the weight ratio of active agent to stabiliser is between 400:1 and 0.5:1.The invention also provides ready-to-use emulsions, e.g. for intravenous administration, prepared using the above process.

REFERENCES:
patent: 5011844 (1991-04-01), Fehr
patent: 5352671 (1994-10-01), Baumann et al.
patent: 5457111 (1995-10-01), Luly et al.
patent: 5665772 (1997-09-01), Cottens et al.
patent: 5932243 (1999-08-01), Fricker et al.
patent: 296122 (1988-12-01), None
patent: 296122 (1988-12-01), None
patent: 0315079 (1989-05-01), None
patent: 0317120 (1989-05-01), None
patent: 0331755 (1989-09-01), None
patent: 0202837 (1989-10-01), None
patent: 0 406 791 (1991-01-01), None
patent: 427680 (1991-05-01), None
patent: 0 484 936 (1992-05-01), None
patent: 0 532 862 (1993-03-01), None
patent: 0570829 (1993-11-01), None
patent: 589843 (1994-03-01), None
patent: 0658344 (1995-06-01), None
patent: 2222770 (1990-03-01), None
patent: 2269536 (1994-02-01), None
patent: 2 278 780 (1994-12-01), None
patent: 61-268625 (1986-11-01), None
patent: 2-502719 (1990-08-01), None
patent: 147892 (1991-05-01), None
patent: WO88/06438 (1988-09-01), None
patent: 8806438 (1988-09-01), None
patent: WO 92/18105 (1992-10-01), None
patent: 93/20833 (1993-10-01), None
patent: WO 95/31969 (1995-11-01), None
patent: 96/13249 (1996-05-01), None
Nell et al., Veterinary Opthamaology, 2005, vol. 8, No. 1, pp. 39-46 (Abstract attached).
Atadja et al., PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug reistance. Cancer and Metastasis Reviews, 1998, vol. 17, pp. 163-168.
The Merk Manual of Diagnosis and Therapy, 1992, 16th Edition, “Keratoconjunctivitis Sicca”, p. 2374.
The Merck Manual of Diagnosis and Therapy, 17thEdition, ed. Beers and Berkow, pp. 720-721.
Stedman's Medical Dictionary, 25thEdition, Illustrated, pp. 344, 2ndcolumn, 1994.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition., pp. 1291-1300, 1996.
Osol, Editor of Remington's Pharmaceutical Sciences, 15th Edition, pp. 1252 and 1253, Jun. 11, 1976.
Windolz, Editor of The Merck Index, 10th Edition, pp. 6706-6707, Jul. 21, 1986.
Derwent Abstract of JP 04253907, (Green Cross Corp.) (1992).
Derwent Abstract of DD 295766 (Arzneimittelwerk Dresda) (1991).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4167576